Clinical Trials Logo

Filter by:
NCT ID: NCT02088697 Completed - Healthy Volunteers Clinical Trials

A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects

Start date: December 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the bioequivalence of ASC-01 Placebo and sertraline Tablet in Japanese healthy male subjects.

NCT ID: NCT02088112 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Start date: March 24, 2014
Phase: Phase 1
Study type: Interventional

This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or metastatic NSCLC subjects

NCT ID: NCT02087943 Completed - Clinical trials for Dermatitis, Atopic Dermatitis

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Start date: June 2014
Phase: Phase 2
Study type: Interventional

A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis

NCT ID: NCT02087059 Completed - Clinical trials for Primary Myelofibrosis (MF)

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Start date: April 2014
Phase: Phase 3
Study type: Interventional

This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.

NCT ID: NCT02085460 Completed - Clinical trials for Head and Neck Cancer

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

Start date: March 2014
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer following administration of rebamipide and to determine the optimal dose of rebamipide.

NCT ID: NCT02082262 Completed - Clinical trials for Conjunctivitis, Allergic

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Start date: March 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.

NCT ID: NCT02082249 Completed - Clinical trials for Advanced Parkinson's Disease

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Start date: March 10, 2014
Phase: Phase 3
Study type: Interventional

This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.

NCT ID: NCT02081625 Completed - Clinical trials for Duchenne Muscular Dystrophy

Exploratory Study of NS-065/NCNP-01 in DMD

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK) of NS-065/NCNP-01 in subjects diagnosed with Duchenne muscular dystrophy (DMD).

NCT ID: NCT02081599 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin in combination with Insulin with an extension treatment for up to 52 weeks.

NCT ID: NCT02081378 Completed - Clinical trials for Chronic Myelogenous Leukemia

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Start date: April 24, 2014
Phase: Phase 1
Study type: Interventional

The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic leukemia (Ph+ ALL) patients who are relapsed or refractory to or are intolerant of Tyrosine kinase inhibitors (TKIs), and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.